Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in ...

Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...

Johnson & Johnson (NYSE:JNJ) announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven ...

Learn about the treatments currently available for HDFN as well as the only therapy in development for this rare disease.

J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label ...

LOG Pharma Primary Packaging, a leading global provider of innovative packaging solutions for the pharmaceutical industry, offers drug manufacturers a complete, integrated packaging solution. By ...

The summary describes the design of Johnson & Johnson's Phase 3 AZALEA trial, which will evaluate the efficacy of nipocalimab in HDFN.

FILE - The New York Stock Exchange is seen in New York, Wednesday, Jan. 29, 2025. (AP Photo/Seth Wenig, File) FILE - The New York Stock Exchange is seen in New York, Wednesday, Jan. 29, 2025. (AP ...